Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mahadevan

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Clinical and Translational Gastroenterology|January 19, 2021
LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced NeoplasiaAzfar Neyaz, Robert D Odze, Steffen Rickelt, et al.
Developmental Cell|August 25, 2023
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8<sup>+</sup> T cellsKrishnan K Mahadevan, Valerie S LeBleu, Elena V Ramirez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 15, 2024
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunityXin Luo, Kathleen M McAndrews, Kent A Arian, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.
Nature Communications|September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlatesValerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Cancer Cell|August 25, 2023
KRAS<sup>G12D</sup> inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8<sup>+</sup> T cellsKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinomaKathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li, et al.
Nature|March 5, 2025
Evolutionary fingerprints of epithelial-to-mesenchymal transitionLuigi Perelli, Li Zhang, Sarah Mangiameli, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Clinical and Translational Gastroenterology|January 19, 2021
LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced NeoplasiaAzfar Neyaz, Robert D Odze, Steffen Rickelt, et al.
Developmental Cell|August 25, 2023
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8<sup>+</sup> T cellsKrishnan K Mahadevan, Valerie S LeBleu, Elena V Ramirez, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 15, 2024
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunityXin Luo, Kathleen M McAndrews, Kent A Arian, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.
Nature Communications|September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlatesValerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Cancer Cell|August 25, 2023
KRAS<sup>G12D</sup> inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8<sup>+</sup> T cellsKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinomaKathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li, et al.
Nature|March 5, 2025
Evolutionary fingerprints of epithelial-to-mesenchymal transitionLuigi Perelli, Li Zhang, Sarah Mangiameli, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Pageof 6